Tri Locum Partners’s Guardant Health GH Stock Holding History

Tri Locum Partners’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-62,600	Closed	-$1.7M	–	61
2022 Q4	$1.7M	Buy	+62,600	New	+$2.86M	0.69%	32

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tri Locum Partners's GH Position: Q2 2023 in Review

Tri Locum Partners sold out of Guardant Health (GH) in Q2 2023, closing a stake of 255,011 shares — an estimated $5.98M sold.

Tri Locum Partners first reported a position in GH in Q2 2022 and held it in 4 quarters. The position peaked at $15.4M in Q3 2022. 300 funds tracked by Wall St. Rank hold GH as of Q2 2023.

Tri Locum Partners reported no remaining Guardant Health position as of Q2 2023 after selling out during the quarter.
Tri Locum Partners sold 255,011 Guardant Health shares in Q2 2023, an estimated $5.98M.
Tri Locum Partners first reported a position in Guardant Health in Q2 2022 and held it in 4 quarters.
Tri Locum Partners's Guardant Health position peaked at $15.4M in Q3 2022.
300 funds tracked by Wall St. Rank held Guardant Health as of Q2 2023.

Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.